FSHD Drug development – Industry Updates

FSHD is one of the most common forms of muscular dystrophy, yet there is currently no approved treatment. Across the world, many companies are working hard to develop effective therapies for people living with FSHD.

 

Two industry partners shared an update on their FSHD drug‑development programs. Epicrispr Biotechnologies reports early clinical data from its first-in-human study and Scholar Rock announced plans to begin a Phase 2 clinical trial of apitegromab for FSHD.

Read full press releases here:

https://epicrispr.com/epicrispr-reports-early-clinical-activity-and-favorable-safety-profile-in-first-in-human-epigenetic-editing-study-for-fshd/

https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-highlights-2026-strategic-priorities